Mersana’s mission is to discover and develop life-changing antibody-drug conjugates for patients fighting cancer.
Mersana has developed highly differentiated and innovative antibody-drug conjugate (ADC) platforms, with both cytotoxic and immunostimulatory payloads, that allow for customization and optimization of ADCs for a given target and indication. As a result, we are designing ADCs to overcome the limitations of first-generation platforms by delivering therapeutics with greater efficacy and tolerability to address the unmet medical needs of people living with cancer.
We are leveraging our proprietary technology platforms to build a robust pipeline of ADCs with the potential to meaningfully improve the lives of people living with cancer. We are pursuing a multiprong strategy for treating cancer with both cytotoxic and immunostimulatory ADCs.
Events & Presentations
February 26, 2021
Mersana Fourth Quarter 2020 Earnings Call
February 24, 2021